Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Luis A. Actis"'
Autor:
Jenny Escalante, Mase Hamza, Brent Nishimura, Meghan Melecio, Carol Davies-Sala, Marisel R. Tuttobene, Tomás Subils, German M. Traglia, Chloe Pham, Rodrigo Sieira, Luis A. Actis, Robert A. Bonomo, Marcelo E. Tolmasky, María Soledad Ramirez
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major human pathogen and a research priority for developing new antimicrobial agents. CRAB is a causative agent of a variety of infections in different body sites. One of the manifesta
Externí odkaz:
https://doaj.org/article/a6f571c4ed79408f97ce03726b0b2a2f
Autor:
Brent Nishimura, Jenny Escalante, Marisel R. Tuttobene, Tomás Subils, Vyanka Mezcord, Camila Pimentel, Nardin Georgeos, Fernando Pasteran, Cecilia Rodriguez, Rodrigo Sieira, Luis A. Actis, Marcelo E. Tolmasky, Robert A. Bonomo, María Soledad Ramirez
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Cefiderocol (CFDC) is a novel chlorocatechol-substituted siderophore antibiotic approved to treat complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-acquired pneumonia (HAP/VAP). Previous work determined that al
Externí odkaz:
https://doaj.org/article/fd541980870846a7a4e6ceae94c0b710
Autor:
Vyanka Mezcord, Jenny Escalante, Brent Nishimura, German M. Traglia, Rajnikant Sharma, Quentin Vallé, Marisel R. Tuttobene, Tomás Subils, Ingrid Marin, Fernando Pasteran, Luis A. Actis, Marcelo E. Tolmasky, Robert A. Bonomo, Gauri Rao, María S. Ramirez
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11752 (2023)
Infections caused by Carbapenem-resistant Acinetobacter baumannii (CRAB) isolates, such as hospital-acquired pneumonia (HAP), bacteremia, and skin and soft tissue infections, among others, are particularly challenging to treat. Cefiderocol, a chloroc
Externí odkaz:
https://doaj.org/article/173835b1945e48288db2fe12d4b1c45e
Autor:
Jenny Escalante, Brent Nishimura, Marisel R. Tuttobene, Tomás Subils, Vyanka Mezcord, Luis A. Actis, Marcelo E. Tolmasky, Robert A. Bonomo, María Soledad Ramirez
Publikováno v:
Biomedicines, Vol 11, Iss 2, p 639 (2023)
The mortality rates of patients infected with Acinetobacter baumannii who were treated with cefiderocol (CFDC) were not as favorable as those receiving the best available treatment for pulmonary and bloodstream infections. Previous studies showed tha
Externí odkaz:
https://doaj.org/article/909bcf69a0264970b6983d2c3df7b3ab
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 12 (2022)
Acinetobacter baumannii is a catalase-positive Gram-negative bacterial pathogen that causes severe infections among compromised patients. Among its noteworthy regulatory mechanisms, this microorganism regulates its lifestyle through the blue light us
Externí odkaz:
https://doaj.org/article/224f6dcd9e3044ada984b9fd4da8b1d6
Autor:
Jennifer T. Grier, Brock A. Arivett, Maria S. Ramírez, Renee J. Chosed, Jessica A. Bigner, Emily J. Ohneck, Maeva L. Metz, Cecily R. Wood, Sergio Arce, Andrea Tartaro, Ryan F. Relich, Luis A. Actis, Steven E. Fiester
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 11 (2021)
Acinetobacter baumannii has been recognized as a critical pathogen that causes severe infections worldwide not only because of the emergence of extensively drug-resistant (XDR) derivatives, but also because of its ability to persist in medical enviro
Externí odkaz:
https://doaj.org/article/9e4258fee103493fb450c61f4b0a57bc
Autor:
Casin Le, Camila Pimentel, Fernando Pasteran, Marisel R. Tuttobene, Tomás Subils, Jenny Escalante, Brent Nishimura, Susana Arriaga, Aimee Carranza, Vyanka Mezcord, Alejandro J. Vila, Alejandra Corso, Luis A. Actis, Marcelo E. Tolmasky, Robert A. Bonomo, Maria Soledad Ramírez
Publikováno v:
Biomedicines, Vol 10, Iss 3, p 600 (2022)
Cefiderocol, a recently introduced antibiotic, has a chemical structure that includes a cephalosporin that targets cell wall synthesis and a chlorocatechol siderophore moiety that facilitates cell penetration by active iron transporters. Analysis of
Externí odkaz:
https://doaj.org/article/d2517f190dfe45c2851f4b1870fb8eb5
Autor:
Maria S. Ramirez, William F. Penwell, German M. Traglia, Daniel L. Zimbler, Jennifer A. Gaddy, Nikolas Nikolaidis, Brock A. Arivett, Mark D. Adams, Robert A. Bonomo, Luis A. Actis, Marcelo E. Tolmasky
Publikováno v:
Frontiers in Microbiology, Vol 10 (2019)
Acinetobacter baumannii A118, a strain isolated from the blood of an infected patient, is naturally competent and unlike most clinical strains, is susceptible to a variety of different antibiotics including those usually used for selection in genetic
Externí odkaz:
https://doaj.org/article/772963d8fbc340d0964b517251fc4197
Autor:
Camila Pimentel, Casin Le, Marisel R. Tuttobene, Tomas Subils, Jasmine Martinez, Rodrigo Sieira, Krisztina M. Papp-Wallace, Niroshika Keppetipola, Robert A. Bonomo, Luis A. Actis, Marcelo E. Tolmasky, Maria Soledad Ramirez
Publikováno v:
Pathogens, Vol 10, Iss 4, p 471 (2021)
Acinetobacter baumannii is a nosocomial pathogen capable of causing serious infections associated with high rates of morbidity and mortality. Due to its antimicrobial drug resistance profile, A. baumannii is categorized as an urgent priority pathogen
Externí odkaz:
https://doaj.org/article/5a29f0c4be2a46fd819926b380401f33
Autor:
Brian M. Luna, Amber Ulhaq, Jun Yan, Paul Pantapalangkoor, Travis B. Nielsen, Bryan W. Davies, Luis A. Actis, Brad Spellberg
Publikováno v:
mSphere, Vol 2, Iss 2 (2017)
ABSTRACT Acinetobacter baumannii is one of the most antibiotic-resistant pathogens in clinical medicine, and extensively drug-resistant (XDR) strains are commonly isolated from infected patients. Such XDR strains are already resistant to traditional
Externí odkaz:
https://doaj.org/article/83a4f617d2854795966090823a1b017a